(BION) BB Biotech - SW
Sector: Healthcare | Industry: Biotechnology | Exchange: SW (Switzerland) | Market Cap: 2.435m CHF | Total Return: 56.9% in 12m
Avg Turnover: 2.68M
Rev. Trend: 93.5%
Warnings
Earnings expected to drop: P/E 3.0 → Forward 11.8
Tailwinds
No distinct edge detected
BB Biotech AG is a Switzerland-based investment company managed by Bellevue Asset Management AG. Established in 1993, the entity focuses on global public equity markets with a specialized concentration on the biotechnology sector. The portfolio is constructed using fundamental analysis to identify companies developing innovative medications and molecular diagnostics.
The biotechnology industry is characterized by high research and development (R&D) expenditures and long regulatory approval cycles, often making diversified investment vehicles a preferred method for managing sector volatility. BB Biotech operates as a closed-end investment company, which allows it to maintain a long-term strategic focus without the immediate pressure of daily fund inflows or outflows. Investors looking for deeper insights into these valuation metrics may find ValueRay a useful resource for further research.
- Net asset value fluctuates with clinical trial results of core holdings
- Interest rate shifts impact valuations of pre-revenue biotech portfolio companies
- Dividend policy sustainability depends on realized capital gains and portfolio performance
- FDA regulatory approvals and drug pricing legislation drive underlying asset volatility
| Net Income: 109.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 7.81 > 1.0 |
| NWC/Revenue: 97.86% < 20% (prev 1.08k%; Δ -983.9% < -1%) |
| CFO/TA 0.12 > 3% & CFO 309.1m > Net Income 109.1m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (55.1m) vs 12m ago 0.64% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 15.87% > 50% (prev 9.22%; Δ 6.65% > 0%) |
| Interest Coverage Ratio: 2.16 > 6 (EBIT TTM 203.4m / Interest Expense TTM 94.2m) |
| A: 0.13 (Total Current Assets 356.4m - Total Current Liabilities 0.0) / Total Assets 2.64b |
| B: 1.00 (Retained Earnings 2.63b / Total Assets 2.64b) |
| C: 0.09 (EBIT TTM 203.4m / Avg Total Assets 2.30b) |
| D: 335.0 (Book Value of Equity 2.63b / Total Liabilities 7.86m) |
| Altman-Z'' = 356.5 = AAA |
As of June 20, 2026, the stock is trading at CHF 44.20 with a total of 77,925 shares traded.
Over the past week, the price has changed by +3.27%,
over one month by +2.91%,
over three months by +2.66% and
over the past year by +56.85%.
BB Biotech has no consensus analysts rating.
P/E Trailing = 3.0344
P/E Forward = 11.8203
P/S = 2.9819
P/B = 0.9194
Revenue TTM = 364.2m CHF
EBIT TTM = 203.4m CHF
EBITDA TTM = 203.4m CHF
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.08b CHF (2.43b + (null Debt) - CCE 356.2m)
Interest Coverage Ratio = 2.16 (Ebit TTM 203.4m / Interest Expense TTM 94.2m)
EV/FCF = 3.36x (Enterprise Value 2.08b / FCF TTM 619.0m)
FCF Yield = 29.78% (FCF TTM 619.0m / Enterprise Value 2.08b)
FCF Margin = 170.0% (FCF TTM 619.0m / Revenue TTM 364.2m)
Net Margin = 29.97% (Net Income TTM 109.1m / Revenue TTM 364.2m)
Gross Margin = unknown ((Revenue TTM 364.2m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.79 (Enterprise Value 2.08b / Total Assets 2.64b)
Interest Expense / Debt = unknown (Interest Expense 94.2m / Debt none)
Taxrate = 0.07% (71.0k / 109.2m)
NOPAT = 203.2m (EBIT 203.4m * (1 - 0.07%))
Current Ratio = unknown (Total Current Assets 356.4m / Total Current Liabilities 0.0)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 203.4m)
Debt / FCF = unknown (Net Debt none / FCF TTM 619.0m)
Total Stockholder Equity = 2.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.76% (Net Income 109.1m / Total Assets 2.64b)
RoE = 4.75% (Net Income TTM 109.1m / Total Stockholder Equity 2.30b)
RoCE = 7.70% (EBIT 203.4m / Capital Employed (Total Assets 2.64b - Current Liab 0.0))
RoIC = 8.90% (EBIT 203.4m / (Assets 2.64b - Curr.Liab 0.0 - Cash 356.2m))
WACC = 7.82% (E(2.43b)/V(2.43b) * Re(7.82%) + (debt-free company))
Discount Rate = 7.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 38.65 | Cagr: 0.63%
[DCF] Terminal Value 77.97% ; FCFF base≈493.2m ; Y1≈565.4m ; Y5≈832.2m
[DCF] Fair Price = 227.1 (EV 12.5b - Net Debt 0.0 = Equity 12.5b / Shares 55.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 93.47 | Revenue CAGR: 12.9k% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-0.61 | Chg30d=-112.36% | Revisions=+20% | GrowthEPS=-105.8% | GrowthRev=+108.3%
EPS next Year (2027-12-31): EPS=-0.66 | Chg30d=-111.79% | Revisions=N/A | GrowthEPS=-8.4% | GrowthRev=+0.0%